SynOx Therapeutics is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies. The company's mission is to establish emactuzumab as a best-in-class drug of choice to address unmet needs and improve the quality of life for as many patients as possible.

SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

COM:SYNOXTHERAPEUTICS

SynOx Therapeutics

Analysis Not Available